首页> 外文OA文献 >PUK9 - NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS

【2h】

PUK9 - NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS

机译：PUK9 - 网络间分析以前未经处理的先进或转移性肾细胞癌的治疗分析，中间体预后差

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
V.A. Laliman; X. Wang; H. Cawston; J. Doan; P. Dale; B. Malcolm;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 早期鼻咽非霍奇金淋巴瘤:不同免疫表型的预后差异和治疗对策分析 [J] . 邹国荣, 张玉晶, 谢方云, 癌症（英文版） . 2006,第012期
2. Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma [J] . Chedgy Edmund C. P., Black Peter C. Urology . 2016,第Null期

机译：Nivolumab：新的第二线治疗晚期肾 - 细胞癌评论：Nivolumab与Everolimus在晚期肾细胞癌中
3. Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma [J] . Chedgy Edmund C. P., Black Peter C. Urology . 2016,第Null期

机译：Nivolumab：晚期肾细胞癌的新二线治疗评论：Nivolumab与依维莫司对晚期肾细胞癌的关系
4. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-na?ve Patients: a Systematic Review and Network Meta-Analysis [J] . Elvira Schmidt, Johanna Lister, Monika Neumann, Targeted oncology . 2018,第2期

机译：Cabozantibib与护理标准比较器进行治疗治疗治疗治疗 - Na've患者：系统审查和网络META分析
5. Integration of Surgery and Systemic Therapy in the Treatment of Locally Advanced and Metastatic Renal Cell Carcinoma [C] . Christopher G. Wood Genitourinary Cancers Symposium . 2011

机译：外科和全身治疗在局部晚期和转移性肾细胞癌中的整合
6. Pharmacotherapeutics Targeting the Hedgehog Pathway: Emerging Treatments for Metastatic Basal Cell Carcinoma [D] . Unsworth, John-Mark. 2018

机译：针对刺猬途径的药物治疗方法：转移基础细胞癌的新兴处理
7. Original research: What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable intermediate and poor risk respectively? A systematic review and network meta-analysis [O] . Guanghui Cao, Xiaoqiang Wu, Zhiwei Wang, 2020

机译：原创研究：分别是高级/转移性肾细胞癌的最佳全身治疗分别是有利中级和差的风险？系统审查和网络元分析
8. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective [O] . Tobias Engel Ayer Botrel, Márcia Datz Abadi, Laura Chabrol Haas, 2021

机译：Pembrolizumab Plus Axitinib和Nivolumab加IpiLimumab作为先进的中间体或贫瘠风险肾细胞癌的一线治疗：从巴西私人视角治疗分析所需的数量

PUK9 - NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS

著录项

引文网络

相似文献

相关主题

期刊订阅